Indoleamine 2,3‐dioxygenase in T‐cell tolerance and tumoral immune escape
Tóm tắt
Từ khóa
Tài liệu tham khảo
Burnet M., 1957, Cancer, a biologic approach, 1, 841
Gutierrez‐Dalmau A, 2007, Immunosuppressive therapy and malignancy in organ transplant recipients, a systematic review, 67, 1167
Penn I., 2000, Post‐transplant malignancy, the role of immunosuppression, 23, 101
Penn I., 1998, Occurrence of cancers in immunosuppressed organ transplant recipients, Clin Transpl, 147
Penn I., 1997, Skin disorders in organ transplant recipients. External anogenital lesions, Arch Dermatol, 133, 221, 10.1001/archderm.1997.03890380093014
Thomas SM, 1993, IFN‐gamma‐mediated antimicrobial response. Indoleamine 2,3‐dioxygenase‐deficient mutant host cells no longer inhibit intracellular Chlamydia spp. or Toxoplasma growth, J Immunol, 150, 5529, 10.4049/jimmunol.150.12.5529
Fujigaki S, 2002, l‐tryptophan‐l‐kynurenine pathway metabolism accelerated by Toxoplasma gondii infection is abolished in gamma interferon‐gene‐deficient mice, cross-regulation between inducible nitric oxide synthase and indoleamine-2,3-dioxygenase, 70, 779
Boyland E, 1955, The estimation of tryptophan metabolites in the urine of patients with cancer of the bladder, Process Biochem, 60, v
Ambanelli U, 1962, Some aspects of tryptophan–nicotinic acid chain in Hodgkin's disease. Relative roles of tryptophan loading and vitamin supplementation on urinary excretion of metabolites, Haematol Lat, 5, 49
Ivanova VD., 1964, Disorders of Tryptophan Metabolism in Leukaemia, Acta Unio Int Contra Cancrum, 20, 1085
Hayaishi O, 1984, Progress in Tryptophan and Seratonin Research, 33
Higuchi K, 1963, Enzymatic formation of D‐kynurenine, Federation Proc, 22, 243
Sugimoto H, 2006, Crystal structure of human indoleamine 2,3‐dioxygenase, catalytic mechanism of O2 incorporation by a heme-containing dioxygenase, 103, 2611
ArefayeneM et al. Identification of functional genetic variants of the indoleamine 2 3 dioxygenase gene. American Association for Cancer Research 97th Annual Meeting Proceedings; 2006 Apr 1–5 Washington DC: 1119.
Brandacher G, 2006, Prognostic value of indoleamine 2,3‐dioxygenase expression in colorectal cancer, effect on tumor-infiltrating T cells, 12, 1144
Muller AJ, 2008, Differential targeting of tryptophan catabolism in tumors and in tumor‐draining lymph nodes by stereoisomers of the IDO inhibitor 1‐methyl‐tryptophan, Int Congr Ser, 1304, 250, 10.1016/j.ics.2007.07.042
Yasui H, 1986, Interferon enhances tryptophan metabolism by inducing pulmonary indoleamine 2,3‐dioxygenase, its possible occurence in cancer patients, 83, 6622
Ozaki Y, 2008, Induction of indoleamine 2,3‐dioxygenase, a mechanism of the anti-tumor activity of interferon gamma, 85, 1242
Mellor AL, 1999, Tryptophan catabolism and T‐cell tolerance, immunosuppression by starvation?, 20, 469
Grohmann U, 2003, Tolerance, DCs and tryptophan, much ado about IDO, 24, 242
Mellor AL, 2004, IDO expression by dendritic cells, tolerance and trytophan catabolism, 4, 762
Wobser M, 2007, Dendritic cell based anti‐tumor vaccination, impact of functional indoleamine 2,3-dioxygenase expression, 56, 1017
Alberati‐Giani D, 1997, Differential regulation of indoleamine 2,3‐dioxygenase expression by nitric oxide and inflammatory mediators in IFN‐gamma‐activated murine macrophages and microglial cells, J Immunol, 159, 419, 10.4049/jimmunol.159.1.419
Daubener W, 1999, Inducible anti‐parasitic effector mechanisms in human uroepithelial cells, tryptophan degradation vs. NO production, 187, 143
Hucke C, 2004, Nitric oxide‐mediated regulation of gamma interferon‐induced bacteriostasis, inhibition and degradation of human indoleamine 2,3-dioxygenase, 72, 2723
Toker A, 2006, Akt signaling and cancer, surviving but not moving on, 66, 3963
Yuan W, 1998, Modulation of cellular tryptophan metabolism in human fibroblasts by transforming growth factor‐beta, selective inhibition of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA synthetase gene expression, 177, 174
Piccirillo CA, 2004, Naturally‐occurring CD4+CD25+ immunoregulatory T cells, central players in the arena of peripheral tolerance, 16, 81
Zenclussen AC, 2005, Abnormal T‐cell reactivity against paternal antigens in spontaneous abortion, adoptive transfer of pregnancy-induced CD4+CD25+ T regulatory cells prevents fetal rejection in a murine abortion model, 166, 811
Karandikar NJ, 1998, Targeting the B7/CD28, CTLA-4 costimulatory system in CNS autoimmune disease, 89, 10
Grohmann U, 1999, IL‐12 acts selectively on CD8 alpha‐ dendritic cells to enhance presentation of a tumor peptide in vivo, J Immunol, 163, 3100, 10.4049/jimmunol.163.6.3100
Orabona C, 2005, Cutting edge, silencing suppressor of cytokine signaling 3 expression in dendritic cells turns CD28-Ig from immune adjuvant to suppressant, 174, 6582
Mantovani A, 2002, Macrophage polarization, tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes, 23, 549
Muller AJ, 2005, Indoleamine 2,3‐dioxygenase in cancer, targeting pathological immune tolerance with small-molecule inhibitors, 9, 831
BanerjeeT et al. A key in vivo antitumor mechanism of action of natural product‐based brassinins is inhibition of indoleamine 2 3‐dioxygenase. Oncogene advance online publication 2007; (DOI DOI:10.1038/sj.onc.1210939).